Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewFK 3311 is a cyclooxygenase-2 (COX-2) inhibitor. Inhibits zymosan-induced prostaglandin E2 production by rat peritoneal neutrophils in vitro and adjuvant-induced arthritis in vivo. Anti-inflammatory.
分子量 | 341.33 |
公式 | C15H13F2NO4S |
储存 | Store at RT |
纯度 | ≥98% (HPLC) |
CAS Number | 116686-15-8 |
PubChem ID | 164009 |
InChI Key | DIIYLGZNZGPXRR-UHFFFAOYSA-N |
Smiles | FC1=CC(F)=CC=C1OC2=C(NS(=O)(C)=O)C=CC(C(C)=O)=C2 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
参考文献是支持产品生物活性的出版物。
Tsuji et al (1992) Studies on antiinflammatory agents. I. Synthesis and pharmacological properties of 2'-phenoxy-methanesulfonanilide derivatives. Chem.Pharm.Bull. 40 2399 PMID: 1446362
Otani et al (2007) Effects of the COX-2 inhibitor FK3311 on ischemia-reperfusion injury in the rat lung. J.Invest.Surg. 20 175 PMID: 17613692
Nakamura et al (1993) Studies on antiinflammatory agents. III. Synthesis and pharmacological properties of metabolites of 4'-acetyl-2'-(2,4-difluorophenoxy)methanesulfonanilide (FK3311). Chem.Pharm.Bull. 41
关键词: FK 3311, FK 3311 supplier, Cyclooxygenase-2, COX-2, inhibitors, inhibits, Oxygenases, Oxidases, FK3311, Cyclooxygenase, 2776, Tocris Bioscience
目前没有该产品的评论。 Be the first to review FK 3311 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.